Market Overview
Molecular diagnostics involves analyzing DNA, RNA, proteins, and other biomarkers to detect diseases, predict treatment responses, and monitor health conditions with high precision. The European market represents a substantial portion of the global molecular diagnostics industry, valued at approximately $5.6 billion in 2025. The sector serves hospitals, diagnostic laboratories, research institutions, and increasingly point-of-care settings across the region.
- •Market size estimated at $5.6 billion in 2025 with projected growth to $8.7 billion by 2034
- •Point-of-care molecular diagnostics sub-market valued at approximately $1.52 billion in 2025
- •Europe holds a significant position in the global molecular diagnostics landscape alongside North America
Growth Drivers
The market expansion is driven by rising incidence of cancer and infectious diseases across Europe, where molecular tests enable earlier and more accurate diagnoses than traditional methods. Aging demographics in countries like Germany, France, and the United Kingdom increase demand for chronic disease management and companion diagnostics. Additionally, the shift toward personalized medicine and targeted therapies requires sophisticated molecular testing to match treatments to individual patient profiles.
- •Growing burden of oncology cases requiring molecular profiling for treatment selection
- •Increased prevalence of infectious diseases driving demand for rapid molecular testing
- •Expanding adoption of companion diagnostics in precision medicine programs
Segmentation and Regional Analysis
The market is segmented by product type, application, and end-user, with infectious disease testing and oncology representing the largest application segments. Western Europe, particularly Germany, France, and the UK, dominates the regional market due to advanced healthcare infrastructure and higher testing adoption. Point-of-care molecular diagnostics is emerging as a fast-growing segment as decentralized testing gains traction outside traditional laboratory settings.
- •Infectious disease and oncology applications drive the largest market shares
- •Western Europe leads regional adoption, with Eastern Europe showing growth potential
- •Point-of-care segment projected to reach $2.17 billion by 2030
Trends and Outlook
What are the recent trends and outlook?
The market is moving toward integration of molecular testing with digital health platforms and artificial intelligence for enhanced data interpretation and workflow automation. Multiplex testing capabilities that detect multiple pathogens or genetic markers simultaneously are gaining adoption to improve efficiency and reduce costs. Over the forecast period, consolidation through mergers and acquisitions is expected as companies seek to broaden their molecular diagnostics offerings and geographic reach.
- •Integration of molecular diagnostics with digital platforms and AI-driven analysis tools
- •Growing demand for multiplex and high-throughput testing solutions
- •Market consolidation anticipated as firms expand portfolios through acquisitions
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.